GlaxoSmithKline, B-291822, April 7, 2003
B-291822: Apr 7, 2003
DIGEST Agency's decision to procure a drug for the treatment of migraine headaches from among four similar drugs solely on the basis of price is reasonable where after a detailed medical review the agency determined that any of these drugs would meet the agency's needs. Award was to be made to "the lowest price. No technical proposals were requested from the offerors. Administration in the management of migraine headaches. /2/ The triptans examined were sumatriptan. Safety and adverse effects associated with each triptan as reported in various published clinical trials. /3/ The review found that all triptan agents are generally well tolerated. That side effects are very similar. That there is insufficient evidence available to conclude that the incidence of other adverse events differs significantly between the triptans.